Pyxis Oncology, Inc.
NASDAQ:PYXSBiotechnology
+$0.11 today
- Market cap
- $168.65M
- Beta
- 1.43
- P/E (TTM)
- -1.6
- EPS (TTM)
- -$1.29
Volume 0.75M
Average 0.50M
PYXS Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
Pyxis Oncology, Inc.NASDAQ: PYXS
Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026
Stock-based compensation outflow shrinks to $0
Q1 FY2026 stock-based compensation was $0, compared with $3.63M a year earlier. Trailing-twelve-month stock-based compensation was $8.17M. Over 3 fiscal years it compounded at -9.2% a year.
Context
- Stock-based compensation amounted to 85.2% of revenue in FY2025, up 5.0 pp from a year earlier.
- Stock-based compensation increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly stock-based compensation holds near $0 or moves back toward the trailing-twelve-month quarterly average of $2.04M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 11.8M USD
- Year-over-year change
- -8.8%
- 4-year CAGR
- +16.3%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 11.8M | -8.8% |
| FY2024 | 2024-12-31 | 12.95M | -23.6% |
| FY2023 | 2023-12-31 | 16.95M | +7.5% |
| FY2022 | 2022-12-31 | 15.76M | +144.7% |
| FY2021 | 2021-12-31 | 6.44M | — |
Stock-Based Compensation vs competitors
How PYXS compares with its peers on the latest reported figures
- PYXS's LTM Mar 2026 stock-based compensation of $8.17M is the 8th largest of the 10 companies compared; the peer median is $11.32M.
- Its year-over-year change of -33.3% is the 7th highest of 10, against a peer median of -32.8%.
- Stock-based compensation amounts to 59.0% of revenue for PYXS, versus a peer median of 68.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $17.5M | -62.1% | -23.7% | — | |
| LTM Mar 2026 | $15.77M | -32.9% | -11.7% | 22.8% | |
| LTM Mar 2026 | $13.6M | -8.6% | +16.5% | 37.3% | |
| LTM Mar 2026 | $11.51M | -28.1% | +4.4% | 5116.0% | |
ZURAZura Bio Limited | LTM Mar 2026 | $11.32M | -37.2% | +233.0% | — |
| LTM Mar 2026 | $11.16M | -32.8% | +2.7% | 99.6% | |
| LTM Mar 2026 | $10.44M | +45.6% | +16.4% | 517.7% | |
| LTM Mar 2026 | $8.17M | -33.3% | -9.2% | 59.0% | |
| LTM Mar 2026 | $7.36M | +42.2% | — | 26.1% | |
| LTM Mar 2026 | $1.52M | -69.5% | — | — | |
| Peer median (excluding PYXS) | $11.32M | -32.8% | +4.4% | 68.4% | |
Competitors are the stored peer set for PYXS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (75.98M) | (120.72M) | (73.79M) | (77.33M) | (79.62M) |
| Depreciation & Amortization | 647K | 709K | 1.93M | 2.98M | 4.51M |
| Deferred Income Tax | 6.28M | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 6.44M | 15.76M | 16.95M | 12.95M | 11.8M |
| Change in Working Capital | 6.68M | 4.5M | (11.66M) | (11.82M) | 1.94M |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 4.64M | (8.33M) | (3.51M) | 1.2M | 6.03M |
| Other Working Capital | 2.03M | 12.83M | (8.16M) | (13.02M) | (4.08M) |
| Other Non-Cash Items | 20.6M | 10.41M | (4.13M) | 15.56M | (2.14M) |
| Operating Cash Flow | (35.33M) | (89.34M) | (70.71M) | (57.67M) | (63.5M) |
| Capital Expenditures | (540K) | (6.4M) | (6.73M) | (237K) | (9K) |
| Acquisitions (Net) | (50K) | 0 | 6.66M | 0 | 0 |
| Purchases of Investments | (50K) | 0 | (196.83M) | (160.12M) | (107.01M) |
| Sales of Investments | 50.05K | 0 | 92.05M | 168.51M | 165.87M |
| Other Investing Activities | (50) | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (590K) | (6.4M) | (104.85M) | 8.16M | 58.86M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 152.3M | 0 | 6.12M | 59.05M | 742K |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 167K | 183K | (193K) | 280K | (148K) |
| Financing Cash Flow | 304.04M | 183K | 5.93M | 59.33M | 594K |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 268.13M | (95.55M) | (169.63M) | 9.81M | (4.05M) |
| Free Cash Flow | (35.87M) | (95.73M) | (77.44M) | (57.91M) | (63.51M) |
Pyxis Oncology, Inc.
NASDAQ:PYXS
Intrinsic Alpha fair value
Locked
Current Price
$1.41
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.